Fortaz — Competitive Intelligence Brief

Fortaz (Ceftazidime) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Third-generation cephalosporin. Area: Metabolic.

marketed Third-generation cephalosporin Bacterial cell wall Metabolic Small molecule

Target snapshot

Fortaz (Ceftazidime) — Pai Holdings Pharm. Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fortaz TARGET	Ceftazidime	Pai Holdings Pharm	marketed	Third-generation cephalosporin	Bacterial cell wall	1985-01-01
Maxipime	Cefepime Hydrochloride	Baxter	marketed	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Piperacillin And Tazobactam	Piperacillin Sodium	Pfizer	marketed	Penicillin-class antibacterial with beta-lactamase inhibitor	Bacterial cell wall; beta-lactamase enzyme	1981-01-01
Ancef In Sodium Chloride 0.9% In Plastic Container	Cefazolin Sodium	GSK	marketed	Cephalosporin	Bacterial cell wall peptidoglycan	1973-01-01
Azithromycin and amoxicillin	Azithromycin and amoxicillin	University of Alabama at Birmingham	marketed	Macrolide and beta-lactam antibiotic combination	Bacterial 50S ribosomal subunit (azithromycin); bacterial cell wall peptidoglycan (amoxicillin)
PPI-amoxicillin-clarithromycin	PPI-amoxicillin-clarithromycin	National Taiwan University Hospital	marketed	Antibiotic combination therapy with acid suppression	Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; clarithromycin targets bacterial ribosome
Aerosolized Tobramycin or Vancomycin	Aerosolized Tobramycin or Vancomycin	Wright State University	marketed	Aminoglycoside antibiotic (tobramycin) / Glycopeptide antibiotic (vancomycin)	Bacterial 30S ribosomal subunit (tobramycin) / Bacterial cell wall peptidoglycan (vancomycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Third-generation cephalosporin class)

1. Abbott · 1 drug in this class
2. Centre Hospitalier Universitaire de Besancon · 1 drug in this class
3. Dr. Damon Scales · 1 drug in this class
4. Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · 1 drug in this class
5. Kamuzu University of Health Sciences · 1 drug in this class
6. Korea United Pharm. Inc. · 1 drug in this class
7. Merck Sharp & Dohme LLC · 1 drug in this class
8. Murdoch Childrens Research Institute · 1 drug in this class
9. Pai Holdings Pharm · 1 drug in this class
10. RESnTEC, Institute of Research · 1 drug in this class